MedTrace Logo

[18F]MC225-PET in Neurodegenerative Disease

NCT05853471 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-05-10

No results posted yet for this study

Summary

P-glycoprotein, an efflux transporter at the blood-brain barrier plays an important role in de development of neurodegenerative disease. A novel PET tracer (\[18F\]MC225) was developed to measure the function of P-glycoprotein and was tested with succes in healthy volunteers. This study aims to evaluate \[18F\]MC225 in neurodegenerative disease.

Conditions

Interventions

DRUG

[18F]MC225

All participants will undergo a PET scan with \[18F\]MC225. No pharmaceutical effects are expected and the study will exclusively have a diagnostic purpose. However, since \[18F\]MC225 is a new PET tracer, it is included in pharmaceutical studies and any study performed with \[18F\]MC225 will be automatically be registered as intervention study.

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Gert Luurtsema, Phd · University Medical Center Groningen

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2024-01-01
Completion
2024-01-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05853471 on ClinicalTrials.gov